| 2026-08-06 | Press release | Press release · Q2 2026 · Aug 2026 |
| 2026-08-06 | 8-K | Form 8-K, Item 2.02 results |
| 2026-08-06 | 10-Q | Form 10-Q for the quarter ended Jun 30 |
| 2026-07-01 | Deck | Investor presentation · Jul 2026 |
| 2026-06-29 | Deck | LumvoaTM (veligrotug-vvze) FDA Approval June 29, 2026 |
| 2026-06-29 | Press release | Viridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa™ (veligrotug-vvze) for the Treatment of Thyroid E |
| 2026-06-29 | 8-K | Form 8-K, Item 7.01 |
| 2026-06-26 | Press release | Download , Viridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa™ (veligrotug-vvze) for the Treatment o |
| 2026-06-03 | Press release | Viridian Therapeutics to Participate in Upcoming June Investor Conferences |
| 2026-06-03 | 8-K | Form 8-K, Item 5.07 |
| 2026-05-28 | 8-K | Form 8-K, Item 1.02 |
| 2026-05-27 | Press release | Download , Viridian Therapeutics to Participate in Upcoming June Investor Conferences, (opens in new windo |
| 2026-05-26 | 8-K | Form 8-K, Item 1.01 |
| 2026-05-11 | 8-K | Form 8-K, Item 1.01 |
| 2026-05-07 | Press release | Viridian Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Progress |
| 2026-05-06 | Press release | Viridian Therapeutics Announces Pricing of Upsized Concurrent Public Offerings of 1.75% Convertible Senior Notes Due 203 |
| 2026-05-05 | Deck | Elegrobart REVEAL-2 Topline Results May 5, 2026 |
| 2026-05-05 | Press release | Viridian Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Progress |
| 2026-05-05 | Press release | Viridian Therapeutics Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032, Common Stock |
| 2026-05-05 | Press release | Download , Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑2 Clinical Trial in C |
| 2026-05-05 | Press release | Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑2 Clinical Trial in Chronic Thyr |
| 2026-05-05 | 8-K | Form 8-K, Item 2.02 results |
| 2026-05-05 | 8-K | Form 8-K, Item 7.01 |
| 2026-05-05 | 10-Q | Form 10-Q for the quarter ended Mar 31 |
| 2026-04-17 | Proxy | Definitive proxy statement |
| 2026-03-30 | Deck | Elegrobart REVEAL-1 Topline Results March 30, 2026 |
| 2026-03-30 | Press release | Download , Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑1 Clinical Trial in A · Q4 2025 |
| 2026-03-30 | Press release | Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑1 Clinical Trial in Active Thyro · Q4 2025 |
| 2026-03-30 | 8-K | Form 8-K, Item 7.01 |
| 2026-02-26 | Press release | Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2025 Financial Results |
| 2026-02-26 | 8-K | Form 8-K, Item 2.02 results |
| 2026-02-26 | 10-K | Annual report on Form 10-K, FY25 |
| 2026-01-08 | Press release | Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-01-06 | Press release | Download , Viridian Therapeutics Prepares for Transformational 2026 |
| 2025-11-05 | 8-K | Form 8-K, Item 2.02 results |
| 2025-11-05 | 10-Q | Form 10-Q for the quarter ended Sep 30 |
| 2025-10-23 | 8-K | Form 8-K, Item 1.01 |
| 2025-10-21 | 8-K | Form 8-K, Item 2.02 results |
| 2025-10-20 | 8-K | Form 8-K, Item 1.01 |
| 2025-08-06 | 8-K | Form 8-K, Item 2.02 results |